Forecast

The analysts' average price target is +12,75€ (+3,16%). The median is +12,44€ (+0,65%).

Buy	16
Hold	7
Sell	1

News Go to news feed

CIBRA Capital boosts Amicus Therapeutics stake in large merger-arbitrage bet

CIBRA Capital disclosed a purchase of 1,476,861 shares of Amicus Therapeutics in its April 24 SEC filing, an estimated $21.17 million trade based on Q1 average pricing. Post-trade the fund holds 1,687,661 shares valued at $24.40 million, representing 11.78% of its reportable AUM and a 10.2% change in AUM. The buy appears to be merger arbitrage ahead of BioMarin’s $14.50-per-share offer for Amicus; if the deal completes CIBRA would earn a modest spread, but failure of the transaction could trigger a sharp share decline. » More on finance.yahoo.com
Amicus Therapeutics reaches 52-week high at $14.46 and shareholders approve takeover

Amicus Therapeutics shares climbed to a 52-week high of $14.46 after rising 115.1% over the past year. Investors point to a strong gross margin of 88.5% and a market capitalization of $4.54 billion. Shareholders narrowly approved the takeover by BioMarin, while Jefferies downgraded its rating to "Hold." Amicus will present new data on treatments for Fabry and Pompe diseases at the WORLDSymposium 2026. » More on de.investing.com
Amicus Therapeutics hits 52-week high ahead of takeover by BioMarin

Shares of Amicus Therapeutics rose to $14.39, marking a 52-week high, driven by a 58.4% gain for the year and a 73% rise over six months. Shareholders approved the acquisition by BioMarin, which values Amicus at $14.50 per share and about $4.8 billion. The company reports a gross profit margin of 88.5% and revenue growth of 20% and will present new study data at the WORLDSymposium 2026; some analysts have cut their ratings and price targets to the takeover price. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Amicus Therapeutics has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Amicus Therapeutics had revenue of 157.86m€ and net profit of 1.44m€

(EUR)	Dec 2025	YoY
Revenue	+157.86m	-
Gross profit	+133.62m	-
Net profit	+1.44m	-
EBITDA	+14.04m	-

Fundamentals

Metric	Value
Market capitalization	+3.90b€
Number of shares	314.00m
52-week high/low	+12,44€ - +4,73€
Dividends	No
Beta	0,48
P/E ratio	−163,73
PEG ratio	+1,68
P/B ratio	+16,33
P/S ratio	+7,17

Company profile

Amicus Therapeutics, Inc. ist ein Biotechnologieunternehmen, das sich auf die Entdeckung, Entwicklung und Bereitstellung von Medikamenten für seltene Krankheiten konzentriert. Zu seinen kommerziellen Produkten und Produktkandidaten gehört Galafold, ein orales Präzisionsmedikament für die Behandlung von Erwachsenen mit einer bestätigten Diagnose der Fabry-Krankheit und einer zugänglichen Galaktosidase-alpha-Genvariante auf der Grundlage von In-vitro-Assay-Daten. Darüber hinaus entwickelt es AT-GAA, ein neuartiges Behandlungsparadigma für die Pompe-Krankheit; Enzymersatztherapien für Pompe-Krankheiten; CLN3, das sich in einer klinischen Phase-1/2-Studie befindet, um die Sicherheit und Wirksamkeit einer einmaligen intrathekalen Verabreichung einer Gentherapie des AAV-Serotyps AT-GTX-502 bei Patienten mit CLN3 zu untersuchen; und CDKL5, ein Gen auf dem X-Chromosom, das für das CDKL5-Protein kodiert, das die Expression essenzieller Proteine für die normale Gehirnentwicklung reguliert. Das Unternehmen hat Kooperations- und Lizenzvereinbarungen mit dem Nationwide Children's Hospital, der University of Pennsylvania und GlaxoSmithKline. Amicus Therapeutics, Inc. wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Philadelphia, Pennsylvania.

Name	Amicus Therapeutics
CEO	Bradley L. Campbell
Headquarters	Philadelphia, pa USA
Website	amicusrx.com
Sector	Materials
Industry	Chemicals
IPO	05/31/2007
Employees	499